W1. Unemo M, Ison CA, Cole M, *et al.* Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union. *Sex Transm Infect* 2013;89:iv42-iv46.

W2. Unemo M, Shipitsyna E, Domeika M. Gonorrhoea surveillance, laboratory diagnosis and antimicrobial susceptibility testing of *Neisseria gonorrhoeae* in 11 countries of the eastern part of the WHO European region. *APMIS* 2011;119:643-9.

W3. Unemo M, Shipitsyna E, Domeika M. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 east European countries: implementation of a *Neisseria gonorrhoeae* antimicrobial susceptibility programme in this region is crucial. *Sex Transm Infect* 2010;86:442-4.

W4. Kunz AN, Begum AA, Wu H, *et al.* Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. *J Infect Dis* 2012;205:1821–9.

W5. Cole MJ, Spiteri G, Town K, *et al.* Risk factors for antimicrobial-resistant *Neisseria gonorrhoeae* in Europe. *Sex Transm Dis* 2014;41:72-9.

W6. Town K, Obi C, Quaye N, *et al.* Drifting towards ceftriaxone treatment failure in gonorrhoea: risk factor analysis of data from the gonococcal resistance to antimicrobials surveillance programme in England and Wales. *Sex Transm Infect* 2017;93:39-45.